Article: Five Abstracts Related to VaxGen's Smallpox Vaccine to be Presented at ASM Biodefense Research Meeting.

BRISBANE, Calif., Jan. 17 /PRNewswire-FirstCall/ -- VaxGen, Inc. (Pink Sheets: VXGN.PK) announced today that five scientific abstracts related to its smallpox vaccine candidate, LC16m8, have been accepted to the February 15-18th, 2006 American Society of Microbiology (ASM) Biodefense Research Meeting in Washington, DC. Researchers will present clinical and pre-clinical data from studies entitled:

 
  -- Safety and Immunogenicity of Attenuated Smallpox Vaccine, LC16m8: 
 Results from a Phase 2 Study 
  -- Clinical Evaluation of Attenuated Smallpox Vaccine LC16m8 in Japan 
  -- Attenuated Smallpox Vaccine LC16m8 Protects Mice from High-Dose Lethal 
 Intranasal ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!